GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...
London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...
China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...
On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...
(Alliance News) - GSK PLC on Friday reported that its Nucala treatment has been approved in China to treat long-term sufferers of a sinus ailment following a phase 3 study.
Jiangxi Shanxiang Pharmaceutical's first generic "Sorafenib" is about to be approved The results of Fujian's centralized procurement of medical consumables are announced, and Johnson & Johnson and ...
INR:7444. bharat rummy circle GlaxoSmithKline's "Mepolizumab" is approved for listing in China Pharmaceutical and Health Industry Weekly Report (June 1st - Ju ...
Mepolizumab is under clinical development by GSK and currently in Phase III for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase III drugs for Chronic Obstructive Pulmonary ...
(Alliance News) - GSK PLC on Friday said a trial of two ovarian cancer treatments met its primary endpoint but did not meet a key secondary target. The First-Engot-OV44 phase III trial evaluated ...
President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study to support the regulatory review process to obtain a new indication for the ...